SOURCE: DNAPrint Genomics, Inc.

October 10, 2006 07:00 ET

DNAPrint Genomics Announces New Services From Ellipsis Biotherapeutics Subsidiary

New Offerings Involve Expansion of Illumina GoldenGate™ and Beckman Coulter SNPstream™ Capabilities

TORONTO and SARASOTA, FL -- (MARKET WIRE) -- October 10, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Ellipsis Biotherapeutics Corporation, its wholly owned subsidiary, has successfully launched several new services in the areas of whole genome association studies and RNA.

The first of Ellipsis' new services utilizes custom and standard panels involving the Illumina GoldenGate™ platform, allowing greater flexibility in mapping DNA sequences. The second service expands its Beckman Coulter SNPstream™ platform to encompass 48plex capacity, one of the fastest and most accurate methods of mapping DNA.

"These new service offerings ensure that Ellipsis is in the forefront of genome research," stated Laurence Rubin, MD, Chief Operating Officer of Ellipsis Biotherapeutics. "We are exhibiting these new offerings this week at the Human Genetics Meeting, along with the Company's full array of firmly established, proprietary genotyping and testing services."

"This is another example of how Ellipsis enhances DNAPrint's diverse service capacity worldwide," stated Richard Gabriel, DNAPrint Genomics' President and CEO. "Dr. Rubin and his team are to be congratulated on their new product offerings, which we expect to become an established benchmark for genomic testing in the future."

Based in Toronto, Ellipsis Biotherapeutics Corporation provides commercial genotyping services, including research capabilities for development of novel genetic tests and gene discovery. As part of its founding mission to investigate genetic susceptibility to inflammatory disease, Ellipsis established fully automated high throughput SNP analysis capabilities. Ellipsis has leveraged this core expertise in human disease research and genetic analysis to provide superior quality genotyping services to government, academic and industrial clients. For more information, visit the Ellipsis website at

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President

    Ron Stabiner
    The Wall Street Group, Inc.